Dec. 5, 2012
/PRNewswire/ -- Actinium Pharmaceuticals reported today that data from two abstracts of studies investigating the company's pipeline hematology product Iomab-B will be presented at the American Society of Hematology's (ASH) 54th Annual Meeting and Exposition in
December 8-11, 2012
). These abstracts include summaries of data from studies in acute myelogenous leukemia, myelodysplastic syndrome (MDS) and acute lymphocytic leukemia (ALL).
Studies presented at this year's ASH meeting will report the complete Phase 2 data set from a study demonstrating that Iomab-B (monoclonal antibody BC8 labeled with Iodine 131) provides a significant survival benefit for high risk AML patients under age 50. At the time of the abstract writing, 36% of the patients were surviving progression free for a median of 87 months. Other data to be presented at the meeting include Phase I dose escalating trial in enabling successful engraftment and complete remissions in transplanting patients who do not have fully matched donors. All the patients in the trial were successfully transplanted and had a complete remission with survival benefit.
The following abstracts will be presented during the 54th Annual ASH Meeting and Exposition:
Abstract #1924: A Phase II Trial Combining Radiolabeled Anti-CD45 Antibody with Fludarabine and Low-Dose Total Body Irradiation (TBI) Followed by Related or Unrelated Hematopoietic Cell Transplantation for Patients Under Age 50 with Advanced Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Saturday, December 8, 2012
5:30 PM - 7:30 PM
(Georgia World Congress Center, Hall B1-B2)
Abstract #4164: Hematopoietic Bone Marrow Transplantation (BMT) for Patients with High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using HLA-Haploidentical Related Donors: A Trial Using Radiolabeled Anti-CD45 Antibody Combined with Immunosuppression Before and After BMT